Pneumolysin is one of the major virulence factors elaborated by Streptococcus pneumoniae; this toxin is a member of the cholesterol-dependent cytolysins. Engagement of cholesterol induces the formation of a multi-subunit complex by pneumolysin that lyses host cells by forming pores on the membrane. Because pneumolysin released by bacteria which have been killed by conventional antibiotics is still active, agents capable of directly attacking the toxin are considered advantageous against antimicrobials in the treatment of S. pneumoniae infections. Here we found that the phytosterol, β-sitosterol, effectively protects against cell lysis caused by pneumolysin. This compound interacts with the toxin at Thr459 and Leu460, two sites important for being recognized by its natural ligand, cholesterol. Similar to cholesterol, β-sitosterol induces pneumolysin oligomerization. This compound also protects cells from damage by other cholesterol-dependent toxins. Finally, this compound protects mice against S. pneumoniae infection. Thus, β-sitosterol is a candidate for the development of anti-virulence agents against pathogens that rely on cholesteroldependent toxins for successful infections.
Scientific RepoRts | 5:17668 | DOI: 10.1038/srep17668 and macrolides. Further complicating treatment is the release of several toxins by S. pneumoniae by the dying bacteria 12 . Agents that target virulence instead of basic bacterial physiology are considered ideal for the treatment of bacterial infection. Together with the immune system of the host, such agents may be able to resolve the infection without exerting selection pressure that can potentially lead to the development of resistance 13 . In this study we investigated the use of a cohort of steroid alcohols derived from plants to test their effects on toxicity, given the fact that pneumolysin is a cholesterol-dependent toxin. We found that β -sitosterol is able to block the cytolytic activity of pneumolysin. Further studies indicate that this compounds exerts its inhibitory effects by competing with cholesterol for binding to the toxin. We also demonstrate that this compound is able to protect mice from lethal infections by S. pneumoniae.
Results
Inhibition of the hemolytic activity of pneumolysin by four sterols. To identify novel avenues for treating infections caused by S. pneumoniae, we attempted to search for natural compounds which are capable of neutralizing the cytotoxicity of pneumolysin. To this end, we examined the effects of four structurally analogous sterols (Fig. 1A) on pneumolysin-mediated cell lysis by measuring their protection of hemoglobin release induced by the toxin. Despite similarity in structure, these four compounds significantly differ in their ability to block PLY-induced hemolysis (Table 1) . Among these, we found that 1 μ g of CHO or BSS is sufficient to neutralize the toxicity of 1 μ g pneumolysin (Table 1 ). In contrast, to exert similar protection against 1 μ g toxin, 32-and 64-μ g of stigmasterol and ergosterol were required, respectively (Table 1) . Because BSS exhibited protection at levels similar to CHO, the natural ligand of pneumolysin, we chose to further analyze its mechanism of action.
BSS has no influence on oligomerization of PLY.
Cell lysis by pneumolysin is believed to occur in a two-step process: CHO first attaches to the membrane where it induces pneumolysin oligomerization which then forms pore in the membrane, disrupting its integrity. Spontaneous oligomerization of pneumolysin occurs when its concentration is higher than 10 mg/ml 14, 15 . Because inhibition of Listeriolysin O oligomerization (another member of the CDC family) by the small molecule compound fisetin leads to abrogation of its toxicity 16 , we thus determined whether β -sitosterol functions by a similar mechanism. Pneumolysin was then incubated with β -sitosterol and the formation of oligomers by the toxin was detected by high performance liquid chromatograph (HPLC). Under experimental conditions, control samples not receiving β -sitosterol were eluted at a retention time of approximately 4.3 min (Fig. 1B) . Pre-incubation with BSS at a concentration of 10 nM did not detectably alter the elution profile of the toxin (Fig. 1B) . These results suggest that BSS does not interfere with the oligomerization of pneumolysin.
β-sitosterol has a high affinity for pneumolysin. To further study its mechanism of action, we determined the potential interactions between BSS and pneumolysin. Recombinant pneumolysin was immobilized on a surface plasmon resonance (SPR) chip and liposomes containing β -sitosterol were used as the mobile phase to examine these interactions.
Our results (Table 2) revealed that BSS has a high affinity for pneumolysin, with a K a of 2.2e3M
, similar to that of CHO (1.66e3M (Fig. 1C,D) . However, when the disassociation constant (K d ) was measured, we found that the BSS-pneumolysin complex has a K D of 8.66e −8 M, which is about 3.65-fold higher than that of the CHO-pneumolysin complex (K D = 2.37e −8 M), indicating that although both molecules bind to pneumolysin with similar affinity, the β -sitosterol -pneumolysin complex is significantly less stable.
BSS protects human lung cells from injury caused by pneumolysin.
In line with its ability to lyse red blood cells, pneumolysin plays a crucial role in cellular damage during the infection of S. pneumoniae in cultured cells such as the human alveolar cell line A549 17 . We thus determined the protective effects of BSS on the toxicity of A549 cells by incubating various amounts of the compound with cells treated with pneumolysin and examined cellular damage by measuring the release of lactate dehydrogenase (LDH). Significant protection is achieved when used at a concentration of 2 μ g/ml, and the cells were almost completely protected in samples receiving 8 μ g/ml BSS (Fig. 1E) .
Residues Thr-459 and Leu-460 are critical for the binding of pneumolysin to β-sitosterol. Previous studies found that besides their participation in the lysis of red blood cells, residues Thr-459 and Leu-460 were also used in PLY cholesterol binding 18 . The structural similarity between BSS and CHO suggests that BSS engages the protein with similar mechanisms. To test this hypothesis, we constructed a pneumolysin mutant in which both Thr-459 and Leu-460 were replaced by a glycine residue. The mutant protein was purified and its interactions with BSS was examined. No interaction was detected between the PLY T459G · L460G mutant and 20 μ M BSS (Fig. S1 ). These results indicate that BSS engages pneumolysin in a similar way to that of CHO. and BSS. Overall, the optimized complexes indicated that BSS binds to pneumolysin in a manner highly similar to that of CHO, which is consistent with the experimental results ( Fig. 2A) . Interestingly, in the predicted BSS-pneumolysin complex, the distance between BSS and Thr459/Leu460 is longer than that seen in the CHO complex (Fig. 2B) . The difference is caused by the alkyl chain of C 25 in BSS, which sterically hindered close interactions between the compound and residues Thr459/Leu460 of pneumolysin. This potential hindrance also provides an explanation to the slightly lower affinity between BSS and the toxin as detected in our SPR analysis ( Table 2 ). The unit for the compounds used is μ g/ml.
Analysis of the interactions between BSS
b The rates of protection were calculated by dividing the OD 543 values to the values obtained by osmatic lysis of sheep red blood cells. BSS protects mice from S. pneumoniae infection. We next extended our study of BSS activity by investigating its protective effects against S. pneumoniae in infections by employing a mouse disease model. To this end, we intranasally infected groups of mice with S. pneumoniae D39 or the pneumolysin-deficient mutant D39-Ply − . A group of mice infected with wild type bacteria were treated with β -sitosterol at 1 hour after infection. Similar infections were established in mice treated with this compound for 1 hour prior to inoculation. The mortality was monitored at predetermined time points. As expected, no death was observed in mice infected with the toxin-defective bacterial strain (Fig. 3A) . In contrast, in the group infected by wild type bacteria, death began to occur 24 hours after infection and approximately 90% of the mice were killed 120 hours after infection (Fig. 3A) . Importantly, when administered with 80 mg/kg body weight, mice infected with the wild type bacterium have been protected and the maximal death rate was 30% during the entire experimental duration (Fig. 3A) , indicating that BSS can effectively protect animal cells from the lethal infection caused by S. pneumoniae. Because the minimal inhibition concentration (MIC) of BSS against S. pneumonia is higher than 2048 μ g/ml, the blood concentration surely will be significantly lower than this. Thus, the observed protection was not due to direct inhibition of bacterial growth by BSS in vivo.
The bacterial burden in the lungs of mice was examined 48 h after infection to evaluate BSS protection. Treatment with BSS prior to or after bacterial challenge led to a marked reduction in bacterial loads. As expectedly, the ply mutant failed to replicate during infection (Fig. 3B,C) .
We also examined the pathology of the lung from mice 48 hours after infection. In lungs from untreated mice infected with D39 WT, the majority of the airspace was obliterated by inflammatory cell infiltrates. Mice treated with β -sitosterol displayed a marked alleviation of pulmonary inflammation indicated by decreased accumulation of cellular infiltrates in the alveolar space (Fig. 3D) .
Discussion
Owing to antibiotic abuse and difficulty in the discovery of new antibiotics, antibiotic resistance is becoming a severe world crisis in the 21 st century. Combating S. pneumoniae infections also faced such a crisis. In 1985, Liu et al found in South Africa, five clinical isolates of S. pneumoniae which displayed tolerance to penicillin 19 . Van-tolerant S. pneumoniae (VTSP) has also recently been identified in some countries 20 . To cope with these challenges, various alternative anti-infection strategies have been pursued, and the development of anti-virulence therapeutics was one such strategies 13 . Pneumolysin (one of the major virulence factors) was found in all clinical isolates of S. pneumoniae [8] [9] [10] . The fact that antibodies specific for pneumolysin provide protection against S. pneumoniae infection 21 made the targeting of this toxin an excellent approach to combat infections caused by S. pneumoniae.
Cholesterol has been long known to be essential for pore formation by CDC toxins and is their exclusive receptor 22 . Earlier studies suggested that the interactions between cholesterol and pneumolysin are highly specific and that the role of cholesterol cannot be replaced by structurally similar sterols 23 . Our identification of β -sitosterol as an inhibitor comparable to cholesterol points to the potential usefulness of this compound for the abrogation of CDC toxicity. Stigmasterol is also active but at a markedly lower potency.
Unlike fisetin, which inhibits the activity of Listeriolysin O (LLO) by interfering with protein oligomerization 16 , β -sitosterol apparently functions by directly competing for the binding site of its natural ligand. Structurally, stigmasterol has a double bond between the C 23 and C 24 atoms, which is absent in cholesterol and β -sitosterol (Fig. 1A) . This double bond might cause the distinct differences in the inhibitory activity of these compounds by placing the side chain in stigmasterol after C 23 on a fixed plane, severely limiting the freedom of rotation allowed in cholesterol and β -sitosterol.
Inhibition of pneumolysin activity affects the ability of S. pneumoniae to colonize the lung, and the bacterium failed to migrate to cerebrospinal fluid (CSF) to exacerbate the infection 11 . The effectiveness of β -sitosterol in the prevention of S. pneumoniae infection may at least complement the use of antibiotics in treatment, as the latter is known to promote the release of pneumolysin complicating treatment of these infections 12 . For example, sub-lytic concentrations of pneumolysin are capable of impairing the function of the alveolar epithelial-capillary barrier, causing a dysfunction of the sodium transporters required for edema reabsorption 12 . The development of permeability edema can be fatal even after the pathogen has been cleared from the lungs by antibiotic treatment 24 . It will be interesting to determine whether administration of β -sitosterol together with antibiotics will allow for better treatment of infections caused by S. pneumoniae.
Our results indicate that the affinity of β -sitosterol to pneumolysin is similar to that of cholesterol but the complexes are not as stable. Such differences may be caused by the branch of C 25 present in BSS, which constitutes the major structural variation among these molecules (Fig. 1A) . This side chain may directly interfere with the binding of β -sitosterol to the toxin or by affecting the positioning of C 27 and C 28 so that they cannot properly interact with Thr459 and Leu460. The exact mechanism underlying such differences still awaits further investigation including the determination of the structure of the complex between β -sitosterol and pneumolysin. Such structural information may allow for chemical modification of this compound to produce molecules with higher efficacy. Methods Bacterial strains and chemicals. S. pneumoniae strains D39 and the ply-deficient mutant D39 MT 17 were used in this study. Cholesterol (CHO), β -sitosterol (BSS), ergosterol and stigmasterol were commercially obtained from Sigma-Aldrich (St. Louis, MO, USA). For in vitro studies, stock solutions of the sterols at various concentrations were made in a mixture of ethyl acetate and DMSO (v/v = 2:8). For in vivo experiments, cytotoxicity assays on cultured cells, Surface Plasmon Resonance (SPR) for interactions with proteins, the effects on protein oligomerization, β -sitosterol or cholesterol was incorporated into liposomes, respectively. Liposome Preparation. An established protocol 25 was used to prepare liposomes. Briefly, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) procured from Avanti Polar Lipids 25 and β -sitosterol or cholesterol were mixed at a molar ratio of 45:55 in chloroform. The solvent was removed with a stream of argon or nitrogen at 40 °C, and the mixture was further dried under vacuum for 3 hours. 500-μ l of the mixture was added to the dried lipids and the suspension was mixed by vortexing and sonication in a water bath for 5 min to ensure that the lipid was fully hydrated. The suspended mixture was then passed 21 times in 0.5 mL increments through an Avestin Inc (Ottawa, ON) liposome extruder to generate liposomes. The liposomes were stored at 4 °C and used within 5 days of preparation.
Cloning, expression and purification of wild-type pneumolysin. The coding sequence of the ply gene was amplified from genomic DNA of S. pneumoniae D39 with primers (forward 5′ -GCTGGATCCCATATGGCAA ATAAAGCAGT-3′ and reverse 5′ -CTGCTCGAGCTAGTCATTTT CTACCTTATC-3′ ), digested with BamHI and XhoI then cloned into similarly digested pET28a to yield pET28a-PLY. This construct was transformed into Escherichia coli BL21 (DE3) cells for protein expression. The cells were grown at 37 °C in LB broth to a density of OD 600 = 0.6 and IPTG was added to a final concentration of 0.2 mM IPTG. After induction at 16 °C for 18 hrs, the cells were harvested by centrifugation. To purify the protein, cells from 4 liters of culture were resuspended in 200 ml PBS and lysed by sonication. The cell lysate was cleared by centrifugation at 30,700g for 30 min. The supernatant was loaded onto a Ni 2+ -NTA agarose column, which had been equilibrated with five column volumes of PBS. The binding was allowed to proceed for 60 min by gentle rocking at 16 o C. The matrix with bound protein was washed with 10× column volumes of a washing buffer (20 mM Tris pH 8.0, 20 mM imidazole 300 mM NaCl). The His 6 -tagged protein was eluted with five column volumes of an elution buffer (20 mM Tris-HCl, 300 mM imidazole and 300 mM NaCl). The eluted protein was concentrated and desalted using Millipore Amicon filters (30 kDa molecular-weight cutoff). The purity of the protein in PBS was analyzed on SDS-PAGE. Pneumolysin mutants were similarly purified.
Hemolysis assay. 10-μ l of purified pneumolysin (100 μ g/ml) was incubated in microtiter plates with serially diluted concentrations of the testing sterols at 37 °C for 15 min. A volume of 50 μ l (5 × 10 6 cell/ml) defibrinated sheep blood in PBS was added to the wells and the final volume of the reaction adjusted to 1 ml with PBS. The reactions were incubated at 37 °C for 25 min. Reactions that received 10-μ l 1% Triton X-100 and PBS were used as positive and negative controls, respectively. Bacteria culture. S. pneumoniae strains D39 and the ply-deficient mutant D39 MT were grown in Todd-Hewitt broth (THB)+ 2% yeast extract (THY media). Bacteria were stored in glycerol at − 70 °C and thawed at room temperature to inoculate fresh liquid THY medium. Bacteria were grown overnight to stationary phase at 37 °C in a 5% CO 2 incubator. These bacterial cells were then diluted to appropriate concentrations.
Oligomerization analysis. 5 nM purified pneumolysin was diluted to 0.4 mM (20 mg/ml) and mixed with 10 nM β -sitosterol-rich liposomes (a total volume of 15 μ l) and incubated at 37 °C for 1 hr. The mixture was injected into an HPLC system (DGU-20A5, SHIMADZU CORPORATION, Japan) equipped with a Nanofilm SEC-250 column (Sepax Technologies, Inc. USA). The flow rate of the mobile phase was set at 0.5 ml/min. Results were plotted with Prism software (GraphPad Software, Inc.). An identical reaction without the addition of β -sitosterol-rich liposomes was established as the untreated control.
Site-directed mutagenesis of ply. Mutations in targeted residues were introduced into the ply gene by using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutations T459G and L460G were introduced in the ply gene in the plasmid pET28a-PLY. The primer pairs used to introduce these two mutations were: T459G-PLY forward, 5′ -TCTATTTGGGGAACA GGTCTCTATCCTCAG-3′ , reverse, 5′-ACCTGTTCCCCAA ATAGAAATCGTCCGCTT-3′ . For L460G-PLY forward, 5′ -ATTTGGGGAACAA CTGGCTATCCTCAGGTA-3′ reverse, 5′-GCCAGTTGTTCCCC AAATAGAAATCG TCCG-3′ . The modified codons were underlined in each primer sequence.
Surface plasmon resonance (SPR) analysis. The affinity and kinetics of pneumolysin, its mutants and cholesterol or β -sitosterol (both as liposome) were measured by SPR at 25 °C on a BIAcore ® 3000 using CM5 chips. Pneumolysin or its T459G/L460G mutant was dissolved in 10 mM sodium acetate (pH 4.0) and immobilized on the CM5 chip with 1000 response units (RU) at a flow rate of 10 μ L/min. Liposomes containing cholesterol or β -sitosterol were serially diluted in PBST buffer (PBS containing 0.005% Tween 20) to concentrations ranging from 20 μ M to 1.25 μ M. Each of the five concentrations used was injected at a flow rate of 30 μ L/min for 2 min; for dissociation, the flow rate was set at 30 μ L/min for 6 min. To regenerate channels, 40 mM β -Octyl glucopyranoside (Sigma-Aldrich St. Louis, MO, USA) was injected for 90 sec at a flow rate of 20 μ L/min, followed by injection of PBST buffer for 90 s until the RU reached the original reading. All injections were performed at 25 °C. The data was fitted with a 1:1 binding model using BIA evaluation 4.1. Figures were made using Prism (GraphPad Software, Inc.).
Molecular modeling. Molecular modeling of the interactions between pneumolysin and cholesterol or β -sitosterol was performed as described previously 16, 26, 27 . The binding free energy between PLY and ligands was calculated by the Molecular Mechanis/Poisson-Boltzman Surface Area (MM-PBSA) method 28 supplied with Amber 10 package 29 . Then, the interaction between inhibitors and each residue in the binding site of PLY was analyzed by using the MM-PBSA decomposition process 30 . The binding of each ligand-residue pair includes three categories: the Van der Waals contribution (Δ Evdw), the electrostatic contribution (Δ Eele), and the salvation contribution (Δ Esol).
Cytotoxicity assays. A549 human lung epithelial cells (ATCC CCL185) were cultured in DMEM medium supplemented with 10% fetal bovine serum (Invitrogen, CA, USA). The cells were seeded in 96-well plates at a density of 1.5 × 10 4 cells per well. 20 μ g of Ply was added to cell cultures containing β -sitosterol at different concentrations. After incubation at 37 °C for 4 h, cell viability was measured by determining extracellular LDH using the Cytotoxicity Detection Kit (LDH) (Roche, Basel, Switzerland) according to the manufacturer's instructions. Briefly, Ply of indicated concentrations was added together with BSS at the testing concentrations to the cells. After incubation at 37 °C, 5% CO 2 for 4 hours, culture supernatant was collected by centrifugation and the LDH activity was measured with a microplate reader (TECAN, Austria). The rates of lysis for the treatment were calculated by dividing the readings to that of Triton X-100 treated samples, in which the cellular LDH was completely released.
Mouse model of intranasal lung infection.
Animal experiments were approved by and conducted in accordance with the guidelines of the Animal Care and Use Committee of Jilin University. 8-week old male C57BL/6 mice were obtained from the Experimental Animal Center of Jilin University.
For lung infection, mice were anesthetized intraperitoneally with ketamine and xylazine and then intranasally infected with a dose of 5 × 10 6 CFU of S. pneumoniae strain D39 in 50-μ l PBS. The bacteria were applied atraumatically to the tip of the left nose and were involuntarily inhaled 31 . For mice groups treated with β -sitosterol, mice were administered with 100-μ l β -sitosterol rich-liposomes subcutaneously 1 hour before or after infection with S. pneumoniae, with additional doses given at 4-hour intervals for 48 hours. Each experimental group contained 20 mice with deaths were recorded at 120 hours at a 24-hour interval.
The bacterial burden in lung tissue samples was evaluated at 48 h postinfection by plating appropriately diluted tissue homogenate on blood agar. Bacteria were enumerated after 24 h incubation.
Statistical analysis.
For mortality studies, statistical analysis was performed with the Fisher's exact test; results in LDH release were analyzed using the two-tailed Student t test.
